Abstract Details

Title The Efficacy of Alpha-Lipoic Acid in Migraine: A Systematic Review and Meta-Analysis

Topic Headache

Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-009

Objective This systematic review aims to assess the current evidence supporting the effectiveness of ALA in migraine prophylaxis

Background While oxidative stress is implicated in migraine pathophysiology, the efficacy of antioxidant-based prophylactic therapies remains unclear. Alpha-lipoic acid (ALA) possesses neuroprotective and anti-inflammatory properties, making it a potential candidate for migraine prevention.

Design/Methods A comprehensive search was conducted on major databases up to April 2024 to identify relevant randomized controlled trials (RCTs). The quality of the studies was assessed using the Cochrane risk of bias tool (ROB2).

Results A total of five RCTs, involving 255 patients were included. The results indicated a significant improvement in migraine mean monthly frequency (MMF) in both ALA as monotherapy and ALA in combination with other treatments groups. The mean difference (MD) for MMF was -1.43 (95% CI: [-2.48, -0.39]; p = 0.007) and -2.32 (95% CI: [-3.18, -1.46]; p = 0.001), respectively. ALA was also effective in reducing migraine mean monthly duration (MMD) (MD = -5.2, 95% CI: [-9.43, -0.98]; p = 0.02). Additionally, ALA led to significantly higher risk of achieving 50% reduction in migraine frequency compared to control group (relative risk = 2.00; 95% CI: [1.34, 3.00]; p = 0.0008). No serious adverse events were reported in any of the included studies.

Conclusions Our findings suggest that ALA is a safe intervention with potential benefits in reducing the frequency of migraines. However, further studies are necessary to strengthen the evidence base and enhance our understanding of its mechanism of action.

Authors/Disclosures
Ahmed Negida, MD, PhD (Virginia Commonwealth University) PRESENTER	Dr. Negida has nothing to disclose.
Obai M. Yousef, Sr., MD	Dr. Yousef has nothing to disclose.
Moaz E. Abouelmagd, MD	Dr. Abouelmagd has nothing to disclose.
Hamdy A. Makhlouf	Mr. Makhlouf has nothing to disclose.
Ahmed Eisa	Dr. Eisa has nothing to disclose.
Amr Elrosasy	Amr Elrosasy has nothing to disclose.

��ɫ��

��ɫ��